Amicus Therapeutics Files 8-K on Shareholder Votes and Exhibits

TL;DR

AMTX filed an 8-K for shareholder votes & financials. All clear.

AI Summary

Amicus Therapeutics, Inc. filed an 8-K on June 7, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing pertains to events on June 6, 2024, with its principal executive offices located at 47 Hulfish Street, Princeton, New Jersey.

Why It Matters

This filing provides important updates on corporate governance and financial reporting for Amicus Therapeutics, which could influence investor decisions.

Risk Assessment

Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating any immediate operational or financial distress.

Key Players & Entities

• AMICUS THERAPEUTICS, INC. (company) — Registrant
• June 6, 2024 (date) — Earliest event reported
• June 7, 2024 (date) — Date of report
• 47 Hulfish Street, Princeton, New Jersey 08542 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock Par Value $0.01 FOLD Nasdaq Indicate by check mar

Filing Documents

• tm2416641d2_8k.htm (8-K) — 41KB
• 0001104659-24-069634.txt ( ) — 210KB
• fold-20240606.xsd (EX-101.SCH) — 3KB
• fold-20240606_lab.xml (EX-101.LAB) — 33KB
• fold-20240606_pre.xml (EX-101.PRE) — 22KB
• tm2416641d2_8k_htm.xml (XML) — 3KB

07 - Submission of Matters to a Vote of Security Holders

Item 5.07 - Submission of Matters to a Vote of Security Holders. At the 2024 Annual Meeting of Stockholders of the Company, held on June 6, 2024, the Company's stockholders elected Eiry W. Roberts, Craig A. Wheeler and Burke W. Whitman as Class II directors to serve a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors have been elected. In addition, the stockholders (i) approved the Amended and Restated 2007 Equity Incentive Plan, (ii) ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, and (iii) approved, on an advisory basis, the compensation paid to the Company's named executive officers. The final voting results on these matters were as follows: 1. Election of Directors. Nominee Votes For Votes Withheld Broker Non-Votes Eiry W. Roberts 248,107,021 6,738,791 11,256,697 Craig A. Wheeler 248,172,753 6,673,059 11,256,697 Burke W. Whitman 245,493,258 9,352,554 11,256,697 2. Approval of the Amended and Restated 2007 Equity Incentive Plan. Votes For Votes Against Votes Abstain Broker Non-Votes 245,475,071 9,101,663 269,078 11,256,697 3. Ratification of Ernst & Young LLC as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023. Votes For Votes Against Votes Abstain Broker Non-Votes 258,841,833 7,207,672 53,004 - 4. Approval, on an advisory basis, of the Company's executive compensation. Votes For Votes Against Votes Abstain Broker Non-Votes 246,376,429 6,826,611 1,642,772 11,256,697

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits: Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Signature Page Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMICUS THERAPEUTICS, INC. Date: June 7, 2024 By: /s/ Ellen S. Rosenberg Name: Ellen S. Rosenberg Title: Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR